Repositioning Candidate Details
| Candidate ID: | R0339 |
| Source ID: | DB01140 |
| Source Type: | approved; vet_approved; withdrawn |
| Compound Type: | small molecule |
| Compound Name: | Cefadroxil |
| Synonyms: | |
| Molecular Formula: | C16H17N3O5S |
| SMILES: | [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O |
| Structure: |
|
| DrugBank Description: | Long-acting, broad-spectrum, water-soluble, cephalexin derivative. |
| CAS Number: | 50370-12-2 |
| Molecular Weight: | 363.388 |
| DrugBank Indication: | For the treatment of the following infections (skin, UTI, ENT) caused by; <i>S. pneumoniae, H. influenzae, staphylococci, S. pyogenes</i> (group A beta-hemolytic streptococci), <i>E. coli, P. mirabilis, Klebsiella</i> sp, coagulase-negative staphylococci and <i>Streptococcus pyogenes</i> |
| DrugBank Pharmacology: | Cefadroxil, a first-generation cephalosporin antibiotic, is used to treat urinary tract infections, skin and skin structure infections, pharyngitis, and tonsillitis. |
| DrugBank MoA: | Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor. |
| Targets: | Penicillin-binding protein 3; Penicillin-binding protein 1A; Penicillin-binding protein 1b; Penicillin-binding protein 2B |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|